Zeitschrift für Rheumatologie

, Volume 71, Issue 6, pp 473–478 | Cite as

Janus-Kinase-Hemmer

Leitthema

Zusammenfassung

Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl für die Mono- als auch die Kombinationstherapie mit Methotrexat. Das Sicherheitsprofil bezüglich Infektionen ist ähnlich zu den bekannten Biologika mit einer Rate an schwerwiegenden Infektionen von 3,0/100 Patientenjahre. Die häufigsten Infektionen stellen Atemwegs- und Harnwegsinfekte dar.

Schlüsselwörter

JAK-Kinase-Hemmer „Small molecules“ Rheumatoide Arthritis Tofacitinib Biologika 

Janus kinase inhibitors

Abstract

Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX). Also the safety profile shows similar infection rates as observed with known biologicals. The crude rate of serious infection events was 3/100 patient-years. Often reported adverse events are infections of the upper respiratory tract and urogenital infections

Keywords

Janus kinase inhibitors Small molecules Rheumatoid arthritis Tofacitinib Biological agents 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Burmester G, Blanco R, Charles-Schoeman C et al (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study. Arthritis Rheum 63(Suppl10):718Google Scholar
  2. 2.
    Cohen S, Radominski SC, et al (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across Phase 3 and long-term extension studies in patients with rheumatoid arthritis. Arthritis Rheum 63(Suppl10):409Google Scholar
  3. 3.
    Cohen S, Zwillich S, Chow V et al (2010) Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 69:143–151PubMedCrossRefGoogle Scholar
  4. 4.
    Fleischmann R, Cutolo M, Genovese Mc et al (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617–629PubMedCrossRefGoogle Scholar
  5. 5.
    Fleischmann R, Kremer J, Connell Ca et al (2011) Oral solo (A3921045): a phase 3 study of oral JAK inhibitor Tofacitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis: subgroup analysis of efficacy-poster tours. Ann Rheum Dis 70(Suppl3):600Google Scholar
  6. 6.
    Fleischmann R, Kremer J, Cush J et al (2010) Phase 3 study of oral JAK inhibitor tasocitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis. Arthritis Rheum #L8; http://www.abstracts2view.com/acr/view.php?nu ( 4352&type ( abstracts&sesId ( 442&num ( CCA&trk ( (Zugegriffen: 24.02.2012)Google Scholar
  7. 7.
    Ghoreschi K, Laurence A, O’shea JJ (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10:356–360PubMedCrossRefGoogle Scholar
  8. 8.
    Heijde D, Tanaka Y, Fleischmann R et al (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatiod arthritis: a 24-month phase 3 study. Arthritis Rheuma 63(Suppl10):2592Google Scholar
  9. 9.
    Hofmann SR, Ettinger R, Zhou YJ et al (2002) Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol 2:495–506PubMedCrossRefGoogle Scholar
  10. 10.
    Kalden JR, Burmester GR, Schmidt RE (2011) Treat to target (T2T). Z Rheumatol 70:639–640PubMedCrossRefGoogle Scholar
  11. 11.
    Kremer J, Li Z-G, Hall S et al (2011) Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis 70(Suppl3):170CrossRefGoogle Scholar
  12. 12.
    Kremer JM, Bloom BJ, Breedveld FC et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895–1905PubMedCrossRefGoogle Scholar
  13. 13.
    Kremer Jm, Cohen S, Wilkinson BE et al (2011) A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. doi: 10.1002/art.33419Google Scholar
  14. 14.
    Pesu M, Laurence A, Kishore N et al (2008) Therapeutic targeting of Janus kinases. Immunol Rev 223:132–142PubMedCrossRefGoogle Scholar
  15. 15.
    Riese RJ, Krishnaswami S, Kremer J (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24:513–526PubMedCrossRefGoogle Scholar
  16. 16.
    Tanaka Y, Suzuki M, Nakamura H et al (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63:1150–1158CrossRefGoogle Scholar
  17. 17.
    Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117–1127PubMedCrossRefGoogle Scholar
  18. 18.
    Vollenhoven RV, Fleischmann R, Cohen SB et al (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a phase 3 study. Arthritis Rheum 63(Suppl 10):408Google Scholar
  19. 19.
    Wollenhaupt J, Silverfield JC, Lee EB et al (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months. Arthritis Rheum 63(Suppl 10):407Google Scholar
  20. 20.
    Yazici Y (2009) Treatment of rheumatoid arthritis: we are getting there. Lancet 374:178–180PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Med. Klinik und Poliklinik II, Sektion Rheumatologie/ImmunologieUniversitätsklinikum WürzburgWürzburgDeutschland

Personalised recommendations